Vernalis of the UK, saw a boost in its share value this morning after reporting positive safety data from a Phase III trial of its migraine drug, Frova (frovatriptan).

The data, which come as the company and partner Endo Pharmaceuticals await the all-important US green light for Frova in menstrually related migraine, show the product to be well-tolerated when used as a six-day dosing regimen for up to six menstrual periods as preventive therapy for MRM. No serious side effects were reported and the study is now nearing completion, with currently more than 300 patients having received 12 months of treatment.

“[Frova’s] distinctively long half-life of 26 hours is a key element in our interest in determining whether it is an appropriate agent for migraine prophylaxis,’ said Simon Sturge, Vernalis’ chief executive. “The interim safety data from this study support our goal of seeking approval for [Frova] for the prevention of MRM.”